🔄 Mebendazole Cancer Research

Mebendazole is an anthelmintic medication traditionally used to treat parasitic worm infections in humans. In recent years, researchers have discovered that this well-established drug demonstrates promising anti-cancer activity in laboratory and preclinical studies. Scientists have identified multiple mechanisms through which mebendazole may interfere with cancer cell growth and survival, including effects on microtubule dynamics and cellular energy production. This unexpected therapeutic potential has generated significant interest in the oncology research community, leading to investigations into whether mebendazole could be repurposed as an off-label cancer treatment.

The study of mebendazole as an anti-cancer agent represents an important example of drug repurposing in cancer research. Because mebendazole has been safely used in clinical practice for decades with a well-understood safety profile, it presents a unique opportunity for rapid translation from laboratory findings to clinical evaluation. Several research groups worldwide are actively investigating its efficacy against various cancer types, though it is important to note that clinical evidence in human cancer patients remains limited at this stage. The mechanisms of action continue to be elucidated through ongoing molecular and cellular research.

This page compiles the latest peer-reviewed research on mebendazole's anti-cancer properties, clinical considerations, and ongoing studies. Whether you are a patient, caregiver, healthcare provider, or researcher seeking current information about this off-label medication in cancer treatment, the articles below represent the most recent scientific findings available. We encourage you to discuss any information found here with your oncology team before making any healthcare decisions.